After two deaths in autoimmune cell therapy trial, Artiva is shutting down
The company is discontinuing AlloNK development and cutting most staff; investigators assessed the two deaths differently.
TL;DR
- Artiva Biotherapeutics said it will wind down after two participants died during a trial of its AlloNK cell therapy for autoimmune conditions.
- Investigators considered one death likely related to the conditioning chemotherapy fludarabine and the second unrelated to treatment, with its cause undetermined.
- The company is stopping the program and reducing its workforce; the cases do not establish that AlloNK caused either death.
Artiva Biotherapeutics said it would wind down and discontinue AlloNK, its natural-killer-cell therapy being studied for autoimmune diseases. The decision followed two deaths among participants in a Phase 2 study, the company and independent reports said. [1] [2]
In the first case, a participant died after a neurological complication. Artiva said an investigator and independent safety review considered the death likely related to fludarabine, a chemotherapy drug used before cell therapy, rather than to AlloNK itself. [1] [2]
A second participant died suddenly about two months after treatment began. The investigator assessed that event as unrelated to AlloNK and other treatment components, while its cause remained undetermined in the company's account. [1] [2]
Artiva said it would cut approximately 94% of its workforce and evaluate strategic alternatives. The findings are specific to the reported trial events; the available reports do not establish a general safety conclusion about other cell therapies. [1] [2]
Why it matters
The case brings attention to how conditioning regimens and investigational cell products are assessed separately when safety events occur, with consequences for trial oversight and the sector's development plans.
Editor's note
Causation is stated as investigators and the company reported it; the second death's cause was not determined.